Segall Bryant & Hamill, LLC Biocryst Pharmaceuticals Inc Call Options Transaction History
Segall Bryant & Hamill, LLC
- $5.57 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCRX
# of Institutions
257Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$158 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$149 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$99.6 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$74 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$69.9 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.47B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...